Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies.
2-year safety and efficacy of bimekizumab, a dual IL-17A and IL-17F inhibitor, has been demonstrated across the full disease spectrum of axial spondyloarthritis (axSpA). We report bimekizumab long-term safety and efficacy over 3 years. Patients completing Week 52 of BE MOBILE 1…